PDF
ePub
Citation
Print
Abstract
Recent studies have shown that inflammatory bowel disease (IBD) patients are affected by altered body composition, especially low muscle mass or sarcopenia. Detection of sarcopenia is important, as it can independently predict osteopenia, sarcopenic obesity, and poor disease outcomes during IBD progress. The challenges are needed to identify diagnostic and managing strategies for sarcopenia in IBD to improve disease outcomes and increase the quality of life in patients with IBD.
References
1. Forbes A, Escher J, Hébuterne X, et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr. 2017; 36:321–347.
2. Hebuterne X, Filippi J, Schneider SM. Nutrition in adult patients with inflammatory bowel disease. Curr Drug Targets. 2014; 15:1030–1038.
3. Schneider SM, Al-Jaouni R, Filippi J, et al. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm Bowel Dis. 2008; 14:1562–1568.
4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010; 39:412–423.
5. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127:990S–991S.
6. Metter EJ, Conwit R, Tobin J, Fozard JL. Age-associated loss of power and strength in the upper extremities in women and men. J Gerontol A Biol Sci Med Sci. 1997; 52:B267–276.
7. Clark BC, Manini TM. What is dynapenia? Nutrition. 2012; 28:495–503.
8. Grimby G, Saltin B. The ageing muscle. Clin Physiol. 1983; 3:209–218.
9. Ryu SW. Clinical characteristics of sarcopenia and cachexia. J Clin Nutr. 2017; 9:2–6.
10. Kim TN. Diverse abnormal body composition penotypes: interaction between muscle, fat, and bone. Korean J Obes. 2015; 24:9–16.
11. Kim TN, Park MS, Yang SJ, et al. Body size phenotypes and low muscle mass: the Korean sarcopenic obesity study (KSOS). J Clin Endocrinol Metab. 2013; 98:811–817.
12. Fearon K, Evans WJ, Anker SD. Myopenia-a new universal term for muscle wasting. J Cachexia Sarcopenia Muscle. 2011; 2:1–3.
13. Scaldaferri F, Pizzoferrato M, Lopetuso LR, et al. Nutrition and IBD: Malnutrition and/or sarcopenia? A practical guide. Gastroenterol Res Pract. 2017; 2017:8646495.
14. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci. 2003; 58:M911–916.
15. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012; 8:457–465.
16. Perandini LA, de Sá-Pinto AL, Roschel H, et al. Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases. Autoimmun Rev. 2012; 12:218–224.
17. Vettor R, Milan G, Franzin C, et al. The origin of intermuscular adipose tissue and its pathophysiological implications. Am J Physiol Endocrinol Metab. 2009; 297:E987–998.
18. van Langenberg DR, Della Gatta P, Hill B, Zacharewicz E, Gibson PR, Russell AP. Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. J Crohns Colitis. 2014; 8:626–634.
19. Hamrick MW. The skeletal muscle secretome: an emerging player in muscle-bone crosstalk. Bonekey Rep. 2012; 1:60.
20. Bryant RV, Ooi S, Schultz CG, et al. Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther. 2015; 41:895–906.
21. Sylvester FA, Gordon CM, Thayu M, et al. Report of the CCFA pediatric bone, growth and muscle health workshop, New York City, November 11–12, 2011, with updates. Inflamm Bowel Dis. 2013; 19:2919–2926.
22. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone? Nat Clin Pract Rheumatol. 2006; 2:35–43.
23. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int. 2000; 11:905–913.
24. Thommesen L, Stunes AK, Monjo M, et al. Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem. 2006; 99:824–834.
25. Shinoda Y, Yamaguchi M, Ogata N, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem. 2006; 99:196–208.
26. Binkley N, Buehring B. Beyond FRAX: it's time to consider "sarco-osteopenia". J Clin Densitom. 2009; 12:413–416.
27. Mager DR, Carroll MW, Wine E, et al. Vitamin D status and risk for sarcopenia in youth with inflammatory bowel diseases. Eur J Clin Nutr. 2018; 72:623–626.
28. Zoico E, Corzato F, Bambace C, et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch Gerontol Geriatr. 2013; 57:411–416.
29. Heber D, Ingles S, Ashley JM, Maxwell MH, Lyons RF, Elashoff RM. Clinical detection of sarcopenic obesity by bioelectrical impedance analysis. Am J Clin Nutr. 1996; 64:472S–477S.
30. Adams DW, Gurwara S, Silver HJ, et al. Sarcopenia Is common in overweight patients with inflammatory bowel disease and may predict need for surgery. Inflamm Bowel Dis. 2017; 23:1182–1186.
31. Bryant RV, Trott MJ, Bartholomeusz FD, Andrews JM. Systematic review: body composition in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 38:213–225.
32. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn's disease clinical course and severity in obese patients. Clin Nutr. 2002; 21:51–57.
33. Olivier I, Théodorou V, Valet P, et al. Is Crohn's creeping fat an adipose tissue? Inflamm Bowel Dis. 2011; 17:747–757.
34. Gambero A, Maróstica M, Abdalla Saad MJ, Pedrazzoli J Jr. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm Bowel Dis. 2007; 13:1357–1364.
35. Holt DQ, Moore GT, Strauss BJ, Hamilton AL, De Cruz P, Kamm MA. Visceral adiposity predicts post-operative Crohn's disease recurrence. Aliment Pharmacol Ther. 2017; 45:1255–1264.
36. Lie MR, Peppelenbosch MP, West RL, Zelinkova Z, van der Woude CJ. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment. Aliment Pharmacol Ther. 2014; 40:1202–1208.
37. Ding NS, Malietzis G, Lung PFC, et al. The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther. 2017; 46:883–891.
38. Bamba S, Sasaki M, Takaoka A, et al. Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn's disease. PLoS One. 2017; 12:e0180036.
39. Zhang T, Cao L, Cao T, et al. Prevalence of sarcopenia and its impact on postoperative outcome in patients with Crohn's disease undergoing bowel resection. JPEN J Parenter Enteral Nutr. 2017; 41:592–600.
40. Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN. Sarcopenia is a novel predictor of the need for rescue therapy in hospitalized ulcerative colitis patients. J Crohns Colitis. 2018 May 12. [Epub ahead of print].
41. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014; 20:2247–2259.
42. Ding NS, Malietzis G, Hart AL. Editorial: anti-TNF therapy and my-openia in Crohn's disease-another step towards personalised medicine. authors' reply. Aliment Pharmacol Ther. 2018; 47:142–143.
43. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015; 149:350–5.e2.
44. Park SW. Sarcopenia of the old age. J Korean Endocr Soc. 2007; 22:1–7.
45. Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition. 2008; 24:694–702.
Table 1.
Categories of Sarcopenia4
XML Download